Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer efficacy while minimizing toxicity, today announced the establishment of a SAB, including world-renowned experts, to advise the Company on the development of candidates from its next-generation CAPTN-3 tri-specific antibody platform. SAB Members:

  • Amir Horowitz, PhD- an expert in natural killer (NK) cell biology and tumor-immune interactions, Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, Icahn School of Medicine at Mount Sinai
  • Afshin Dowlati, MD- Professor, Department of Medicine and Associate Director for Clinical Research, Case Comprehensive Cancer Center at Case Western Reserve University with extensive experience in early-phase clinical development of T-cell engager therapies in solid tumors, including DLL3-targeted approaches.
  • Alexander Shoushtari, MD- Associate Attending Physician, Melanoma Medical Oncologist and Cellular Therapist at Memorial Sloan Kettering Cancer Center and clinical investigator involved in the development of tebentafusp, one of the first approved T-cell engager therapies in solid tumors.
  • Max S. Topp, MD- Head of Hematology and Associate Professor for Translational Immunology at the Universitätsklinikum Würzburg, Germany Medical Clinic who played a key role in the early clinical development of blinatumomab, one of the first approved bispecific T-cell engager therapies.

"The newly established SAB brings together leading experts in T cell and NK engagers development, tumor immunology, and clinical oncology, including clinicians and scientists with direct experience in the development of some of the first approved and foundational therapies in the field. The SAB will provide strategic guidance as Purple advances our CAPTN-3 platform development." said Gil Efron, Chief Executive Officer of Purple Biotech. "CAPTN-3 represents a differentiated approach to immunotherapy, combining conditional activation with multi-mechanism immune engagement. As we advance toward clinical development, we believe it is critical to bring together advisors with deep expertise across both the biology and clinical dimensions of T-cell engagers. We are pleased to assemble a group with direct experience in developing and advancing these types of therapies into the clinic."